Pharsight

Filspari patents expiration

FILSPARI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9993461 TRAVERE Method for treating disorders associated with glomerular function
Mar, 2030

(5 years from now)

Filspari is owned by Travere.

Filspari contains Sparsentan.

Filspari has a total of 1 drug patent out of which 0 drug patents have expired.

Filspari was authorised for market use on 17 February, 2023.

Filspari is available in tablet;oral dosage forms.

Filspari can be used as treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression.

Drug patent challenges can be filed against Filspari from 17 February, 2027.

The generics of Filspari are possible to be released after 29 March, 2030.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-389) Feb 17, 2030
New Chemical Entity Exclusivity(NCE) Feb 17, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using SPARSENTAN ingredient

NCE-1 date: 17 February, 2027

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression

Dosage: TABLET;ORAL

More Information on Dosage

FILSPARI family patents

Family Patents